Clinical Trials Using Activated Marrow Infiltrating Lymphocytes

Clinical trials are research studies that involve people. The clinical trials on this list are studying Activated Marrow Infiltrating Lymphocytes. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • Tadalafil and Lenalidomide with or without Activated Marrow Infiltrating Lymphocytes in Treating Patients with High-Risk Multiple Myeloma Undergoing Stem Cell Transplant

    This randomized phase II trial studies how well tadalafil and lenalidomide with or without activated marrow infiltrating lymphocytes work in treating patients with multiple myeloma undergoing stem cell transplant. Activated marrow infiltrating lymphocytes are blood and bone marrow cells that are stimulated to react to certain proteins and may help to target and kill cancer cells. Tadalafil may increase the possibility of trafficking activated marrow infiltrating lymphocytes to the cancer site. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. It is not yet known whether giving tadalafil and lenalidomide is more effective with or without activated marrow infiltrating lymphocytes in treating patients with multiple myeloma.
    Location: 3 locations

  • Activated Immune Cells in Treating Patients with Hematologic Cancers That Have Relapsed after Donor Stem Cell Transplant

    This phase I trial studies a type of biological therapy that uses activated immune cells, called activated marrow infiltrating lymphocytes (aMILs), to treat patients with cancers of the blood or bone marrow that have returned after a stem cell transplant from a donor. aMILs are blood and bone marrow cells that are stimulated to react to certain proteins and grow and expand in the laboratory. This may cause the cells to target and kill cancer cells.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland